COMPATIBILITY STUDIES OF FUSIDIC ACID WITH PHARMACEUTICAL EXCIPIENTS TO DEVELOPMENT CREAM NOVEL DRUG DELIVERY SYSTEMS FOR ENHANCED DIABETIC WOUND HEALING
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | Englisch |
| Veröffentlicht: |
Zenodo
2026
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901713770774528 |
|---|---|
| author | Abdalwali Ahmed Saif1, Mahmoud Mahyoob Alburyhi1*, Maged Alwan Noman1, Amina El-Shaibany2 |
| author_facet | Abdalwali Ahmed Saif1, Mahmoud Mahyoob Alburyhi1*, Maged Alwan Noman1, Amina El-Shaibany2 |
| contents | <p><span>Chronic diabetic wounds are challenging to treat due to combined issues of impaired tissue repair and high infection risk. Fusidic Acid (an antibiotic effective against skin pathogens including MRSA) each address different facets of diabetic wound pathology. The main objective of the present study was to the preformulation studies were performed to know the development of formulation and evaluation of Fusidic Acid Cream NDDS for topical application. In the present study that the compatibility was assessed by, FTIR spectroscopy, and melting point apparatus, preformulation parameters. Results showed that physical mixtures of Atorvastatin and various excipients such as </span><span>cetostearyl alcohol, stearic acid, Vaseline (petroleum jelly), liquid paraffin, antioxidant: butylated hydroxyanisole (BHA), preservative: chlorocresol, aqueous phase components: propylene glycol, and emulsifier: Tween 80 </span><span>were evaluated for preformulation studies parameters were investigated by FTIR it was detected that there was no variation or minor deviation in the characteristic peaks in FTIR </span><span>spectroscopy. It was concluded that the </span><span>drug </span><span>Fusidic Acid was found to be compatible with various excipients which were selected for the formulation development of the</span><span> </span><span>Fusidic Acid Cream NDDS</span><span>. </span><span>These formulations favorable properties and efficacy indicate it as a promising strategy for improving outcomes in infected diabetic wounds. Formulation scientist from his experience and knowledge have to significantly in the preformulation study stage and is an important factor in the NDDS (Novel Drug Delivery Systems) product development process. </span></p> <p class="MsoNormal"><span> </span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20266189 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | COMPATIBILITY STUDIES OF FUSIDIC ACID WITH PHARMACEUTICAL EXCIPIENTS TO DEVELOPMENT CREAM NOVEL DRUG DELIVERY SYSTEMS FOR ENHANCED DIABETIC WOUND HEALING Abdalwali Ahmed Saif1, Mahmoud Mahyoob Alburyhi1*, Maged Alwan Noman1, Amina El-Shaibany2 <p><span>Chronic diabetic wounds are challenging to treat due to combined issues of impaired tissue repair and high infection risk. Fusidic Acid (an antibiotic effective against skin pathogens including MRSA) each address different facets of diabetic wound pathology. The main objective of the present study was to the preformulation studies were performed to know the development of formulation and evaluation of Fusidic Acid Cream NDDS for topical application. In the present study that the compatibility was assessed by, FTIR spectroscopy, and melting point apparatus, preformulation parameters. Results showed that physical mixtures of Atorvastatin and various excipients such as </span><span>cetostearyl alcohol, stearic acid, Vaseline (petroleum jelly), liquid paraffin, antioxidant: butylated hydroxyanisole (BHA), preservative: chlorocresol, aqueous phase components: propylene glycol, and emulsifier: Tween 80 </span><span>were evaluated for preformulation studies parameters were investigated by FTIR it was detected that there was no variation or minor deviation in the characteristic peaks in FTIR </span><span>spectroscopy. It was concluded that the </span><span>drug </span><span>Fusidic Acid was found to be compatible with various excipients which were selected for the formulation development of the</span><span> </span><span>Fusidic Acid Cream NDDS</span><span>. </span><span>These formulations favorable properties and efficacy indicate it as a promising strategy for improving outcomes in infected diabetic wounds. Formulation scientist from his experience and knowledge have to significantly in the preformulation study stage and is an important factor in the NDDS (Novel Drug Delivery Systems) product development process. </span></p> <p class="MsoNormal"><span> </span></p> |
| title | COMPATIBILITY STUDIES OF FUSIDIC ACID WITH PHARMACEUTICAL EXCIPIENTS TO DEVELOPMENT CREAM NOVEL DRUG DELIVERY SYSTEMS FOR ENHANCED DIABETIC WOUND HEALING |
| url | https://doi.org/10.5281/zenodo.20266189 |